Program
BI 765423
A development code.
In Boehringer Ingelheim's pipeline, IL-11 antibody
. Its studies are mostly in Idiopathic Pulmonary Fibrosis, led by Boehringer Ingelheim.
Furthest: phase 2, since Jun 17, 20253 company-led studies, 1 open or runningNext primary completion: Mar 11, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 31 open or running | phase 2since Jun 17, 2025 | Dec 13, 2022 | Mar 11, 2027phase 2 · NCT07036523 |
- Named in Boehringer Ingelheim’s own pipeline as
BI 765423
, phase 2, as of Aug 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 13, 2022First study: phase 1 study in HealthyFirst studyNCT05658107 · 64 enrolled · Belgium
- Jan 22, 2024Phase 1 study in HealthyNCT06232252 · 38 enrolled · Belgium
- Jun 17, 2025Phase 2 study in Idiopathic Pulmonary FibrosisNCT07036523 · 81 enrolled · United States, Australia, Belgium and more
Ahead
- Mar 11, 2027Primary completion: phase 2 study in Idiopathic Pulmonary FibrosisNCT07036523
TargetBeta
“IL-11 antibody”the company's pipeline, read by Claude · source
Other programs on IL11
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-IL-11 Monoclonal Antibody 9MW3811rule | Mabwell (Shanghai) Bioscience | phase 2 | 4 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07036523Idiopathic Pulmonary Fibrosis · United States, Australia, Belgium and more | 2 | Active, not recruiting | Mar 11, 2027 | 81 |
| NCT06232252Healthy · Belgium | 1 | Completed | Apr 25, 2025 | 38 |
| NCT05658107Healthy · Belgium | 1 | Completed | Mar 19, 2024 | 64 |
How it is read
Names in the registry
- “BI 765423”, 3 entries
Codes read as this program: BI765423.
Conditions, from the studies’ own filings
- Idiopathic Pulmonary Fibrosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.